HLA-DRB1*14等位基因对阿德福韦酯治疗HBeAg阳性慢性乙型肝炎疗效的影响

摘要

Objective To investigate the influence of the human leukocyte antigen( HLA )-DRBl * 14 allele on the treatment of HBeAg-positive chronic hepatitis B with adefovir dipivoxil. Methods HLA-DRB1 * 14 allele was detected in 65 patients with HBeAg-positive chronic hepatitis B( case group ) and 70 healthy controls( control group ) by using the polymerase chain reaction sequence specific primer( PCR-SSP ). Patients in case group treated with adefovi dipivoxil were divided into effective group and ineffective group, and the frequencies of HLA-DRB1 * 14 were analyzed between the two groups. Results No significant difference was found in HLA-DRB1 * 14 allele frequencies between case group and control group( 15.7% vs 15.4% ,P >0.05 ) or between effective group and ineffective group( 15.6% vs 15.2% ,P >0.05 ). Conclusion The frequency of HLA-DRB1 * 14 allele in the patients with HBeAg-positive chronic hepatitis B is basically identical with that in normal control subjects. HLA-DRB1 * 14 allele has no significant effect on the treatment of HBeAg-positive chronic hepatitis B with adefovi dipivoxil.%目的 探讨HLA-DRB1*14等位基因对阿德福韦酯(ADV)治疗HBeAg阳性慢性乙型肝炎疗效的影响.方法 采用序列特异性引物聚合酶链反应技术(PCR-SSP)检测65例HBeAg阳性慢性乙型肝炎患者(病例组)和70例健康人(对照组)等位基因HLA-DRBI*14,比较阿德福韦酯治疗有效组和无效组中HLA-DRB1*14等位基因阳性率.结果 病例组、对照组HLA-DRB1*14等位基因阳性率分别为15.7%和15.4%,两组差异无统计学意义(P＞0.05);治疗有效组HLA-DRB1*14等位基因阳性率为15.6%,无效组为15.2%,两组差异无统计学意义(P＞0.05).结论 HLA-DRB1*14等位基因在HBeAg阳性慢性乙型肝炎患者和健康人群的分布基本一致,该基因对阿德福韦酯治疗HBeAg阳性慢乙肝疗效无明显影响.